AstraZeneca's new formulation of systemic lupus erythematosus (SLE) therapy Saphnelo has been turned down by the FDA, despite getting the go-ahead in Europe a few weeks ago. The US regulator has ...
Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus erythematosus (SLE) have been revealed, and have not disappointed.
Everyday Health’s team of board-certified physicians and health professionals contribute to the creation and review of content, ensuring that the information is useful, up to date, and accurate. Susan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results